Envoy Medical COCH R&D credit carryforward
R&D credit carryforward at other companies
Other financials
Where this comes from
Reported directly by Envoy Medical in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.
The official record: Envoy Medical’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Envoy Medical's r&d credit carryforward.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Envoy Medical's r&d credit carryforward?
- Envoy Medical (COCH) reported r&d credit carryforward of $31K in Q4 2025.
- What is the long-term trend for Envoy Medical's r&d credit carryforward?
- Over 3 years (2022 to 2025), Envoy Medical's r&d credit carryforward has grown at a -60.4% compound annual growth rate (CAGR), from $500K to $31K.
- What does r&d credit carryforward mean?
- This metric represents the accumulated value of research and development tax credits that a company has earned but has not yet utilized to offset future tax liabilities. It reflects potential future tax savings that can be realized once the company generates sufficient taxable income. For a blank check company, this asset typically represents historical tax attributes preserved for future business combinations or operational activities.